Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress Media ReleaseCOPENHAGEN, Denmark; May 14, 2024 Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development programThree oral presentations highlight novel data evaluating epcoritamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL), in combination for first-line treatment of diffuse large B-cell lymphoma (DLBCL),...
>EBITDA decline less pronounced than feared - At a group level, Bayer’s Q1 sales of € 13.8bn (-4.3%), was below our (€ 14.0bn) and the consensus estimates (€ 14.1bn), the group’s EBITDA of € 4,412m (-1.3%) came in stronger than we expected (€ 4,188m) and was 6.4% above the consensus. The group’s EBITDA decline vs Q1 2023 was driven by the Crop Science divisions, where a decrease in glyphosate-based herbicides and cost inflation weighed on earnings. On the back of the ...
Iliad abonde les obligations Iliad Holding 2031 à hauteur de 150 m EUR et 200 m USD Grifols : S&P confirme le rating corporate B avec une perspective stable (vs. B/cw negative) Delivery Hero : cession de foodpanda à Uber pour 950 m USD + augmentation de capital réservée de 300 m USD>...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, COLONIAL, FERROVIAL, GRIFOLS, LOGISTA, NH HOTELES, UNICAJA. EUROPA: BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’24 que se publicarán en España y Europa en los próximos días. Jornada de transición en las bolsas En una sesión sin referencias macroeconómicas y con la campaña de resultados com...
Costs are under control, but an increase in sales in H2/FY 24 is necessary to achieve the bottom line of guidance FY24, which is now qualified as "ambitious". Once there is more clarity on this, the guidance will be specified. The guidance FY24will now only be raised by the D.O.R.C. top-line contribution (FY24: approx. € 100m; D.O.R.C. bottom-line contributions (incl. ppa) will follow later).
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 13, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from May 6, 2024 to May 10, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 689,510 1,393,154,997.08May 6, 2...
Die Kosten sind im Griff, doch ist eine Umsatzausweitung im H2/FY 24 nötig, um die inzwischen als „ambitioniert“ qualifizierte bottom-line der Guidance 24 zu erreichen. Wenn hierüber mehr Klarheit herrscht, wird die 24er Guidance konkretisiert werden. Die 24er Guidance wird jetzt nur um den D.O.R.C.-Topline-Beitrag (FY 24: ca. € 100 Mio.) angehoben (D.O.R.C.-Bottomline-Beiträge (inkl. ppa) folgen später).
>Q2 review – miss on top line and adj. EBIT - Q2 2024 revenues € 472.1m (-6.4% y-o-y) were driven by a constant currency decline of c. 0.7% and a forex headwind of 570bp, or -7%/-7% vs ODDO BHF/consensus. EBIT of € 64.7m (-22.7% y-o-y, margin 13.7%) was 11%/17% ahead of expectations pushed by Topcon settlement. Adj. EBIT reached € 49.0m (-43.2% y-o-y, margin 10.4%) and was -3%/-13% vs consensus. EPS of € 0.52 compares to expectations of € 0.49 and € 0.46 for the conse...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.